EBV-activation of human B-lymphocytes.

[1]  J. Habeshaw,et al.  Expression of burkitt lymphoma‐associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal‐centre B cells , 1985, International journal of cancer.

[2]  T. Schulz,et al.  Growth control of activated, synchronized murine B cells by the C3d fragment of human complement , 1985, Nature.

[3]  S. Swerdlow,et al.  Distribution of B lymphocyte subsets in normal lymphoid tissue. , 1984, Clinical and experimental immunology.

[4]  G. Klein,et al.  Epstein-Barr virus susceptibility of normal human B lymphocyte populations , 1984, The Journal of experimental medicine.

[5]  I. Magrath,et al.  T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals. , 1982, Journal of immunology.

[6]  A G Bird,et al.  A New Approach to the Study of Human B Lymphocyte Function Using an Indirect Plaque Assay and a Direct B Cell Activator , 1979, Immunological reviews.

[7]  W. Leibold,et al.  Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation , 1976, Infection and immunity.

[8]  G. Klein,et al.  Cellular localization of an Epstein‐Barr virus (EBV)‐associated complement‐fixing antigen in producer and non‐producer lymphoblastoid cell lines , 1973, International journal of cancer.

[9]  P. Åman,et al.  TPA (12-O-tetradecanoyl-phorbol-13-acetate) activation and differentiation of human peripheral B lymphocytes. , 1984, Immunology.